

Sergi Mas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8777830/publications.pdf>

Version: 2024-02-01

98
papers

1,750
citations

218662

26
h-index

377849

34
g-index

110
all docs

110
docs citations

110
times ranked

2609
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E46-E55.	2.4	65
2	A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2009, 9, 404-410.	2.0	50
3	Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 531-538.	1.5	49
4	Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 71-77.	4.8	47
5	Effects of milk supplementation with conjugated linoleic acid (isomers cis-9, trans-11 and trans-10,) Tj ETQq1 1 0.784314 rgBT /Overl 98, 860-7.	2.3	45
6	Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. <i>Schizophrenia Research</i> , 2007, 90, 115-122.	2.0	45
7	Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2014, 48, 94-101.	3.1	45
8	Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. <i>Pharmacogenomics Journal</i> , 2014, 14, 457-462.	2.0	43
9	Modelling gene-environment interaction in first episodes of psychosis. <i>Schizophrenia Research</i> , 2017, 189, 181-189.	2.0	43
10	Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. <i>Psychiatry Research</i> , 2008, 161, 131-141.	3.3	42
11	Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder. <i>Journal of Neuroinflammation</i> , 2017, 14, 261.	7.2	42
12	Exon-focused genome-wide association study of obsessive-compulsive disorder and shared polygenic risk with schizophrenia. <i>Translational Psychiatry</i> , 2016, 6, e768-e768.	4.8	41
13	Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with schizophrenia in a Spanish population. <i>Psychiatry Research</i> , 2009, 165, 175-180.	3.3	38
14	Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive disorder. <i>Journal of Affective Disorders</i> , 2015, 186, 284-292.	4.1	38
15	CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 807-811.	1.9	36
16	Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. <i>Pharmacogenomics Journal</i> , 2012, 12, 255-259.	2.0	35
17	Common genetic background in anorexia nervosa and obsessive compulsive disorder: Preliminary results from an association study. <i>Journal of Psychiatric Research</i> , 2013, 47, 747-754.	3.1	35
18	DNA Cards: Determinants of DNA Yield and Quality in Collecting Genetic Samples for Pharmacogenetic Studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 101, 132-137.	2.5	32

#	ARTICLE	IF	CITATIONS
19	Examining Gene-Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. <i>Schizophrenia Bulletin</i> , 2020, 46, 1019-1025.	4.3	32
20	Fluoxetine pharmacogenetics in child and adult populations. <i>European Child and Adolescent Psychiatry</i> , 2012, 21, 599-610.	4.7	30
21	Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway. <i>European Neuropsychopharmacology</i> , 2015, 25, 51-59.	0.7	30
22	Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naïve first-episode schizophrenia and healthy controls. <i>Translational Psychiatry</i> , 2015, 5, e626-e626.	4.8	30
23	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. <i>Pharmacogenomics Journal</i> , 2016, 16, 439-445.	2.0	30
24	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv121.	2.1	29
25	Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 28-34.	4.8	28
26	Plasma Fluoxetine Concentrations and Clinical Improvement in an Adolescent Sample Diagnosed With Major Depressive Disorder, Obsessive-Compulsive Disorder, or Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 318-326.	1.4	27
27	-141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population. <i>Psychiatric Genetics</i> , 2008, 18, 122-127.	1.1	25
28	SIMULTANEOUS GENOTYPING OF CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS IN A SPANISH POPULATION THROUGH MULTIPLEX LONG POLYMERASE CHAIN REACTION AND MINISEQUENCING MULTIPLEX SINGLE BASE EXTENSION ANALYSIS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 992-997.	1.9	23
29	Association of A/G Polymorphism in Intron 13 of the Monoamine Oxidase B Gene with Schizophrenia in a Spanish Population. <i>Neuropsychobiology</i> , 2008, 58, 65-70.	1.9	21
30	Integrating Genetic, Neuropsychological and Neuroimaging Data to Model Early-Onset Obsessive Compulsive Disorder Severity. <i>PLoS ONE</i> , 2016, 11, e0153846.	2.5	21
31	Induction of Apoptosis in HT-29 Cells by Extracts from Isothiocyanates-rich Varieties of <i>Brassica Oleracea</i> . <i>Nutrition and Cancer</i> , 2007, 58, 107-114.	2.0	20
32	Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 712-721.	1.9	20
33	Altered frequencies of Th17 and Treg cells in children and adolescents with obsessive-compulsive disorder. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 608-616.	4.1	20
34	Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. <i>Human Psychopharmacology</i> , 2013, 28, 586-593.	1.5	19
35	Role of <i>GAD2</i> and <i>HTR1B</i> genes in early-onset obsessive-compulsive disorder: results from transmission disequilibrium study. <i>Genes, Brain and Behavior</i> , 2014, 13, 409-417.	2.2	19
36	Lower specific micronutrient intake in colorectal cancer patients with tumors presenting promoter hypermethylation in p16(INK4a), p4(ARF) and hMLH1. <i>Anticancer Research</i> , 2007, 27, 1151-6.	1.1	19

#	ARTICLE	IF	CITATIONS
37	Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2014, 15, 580-584.	1.7	18
38	Network analysis of gene expression in peripheral blood identifies mTOR and NF- κ B pathways involved in antipsychotic-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2015, 15, 452-460.	2.0	18
39	Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. <i>Psychiatry Research</i> , 2010, 175, 173-175.	3.3	17
40	Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. <i>Pharmacogenomics</i> , 2012, 13, 1773-1782.	1.3	17
41	Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies. <i>European Neuropsychopharmacology</i> , 2013, 23, 329-337.	0.7	17
42	Relationship between <i>CYP2D6</i> genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1551-1563.	1.3	16
43	Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 77, 236-240.	4.8	16
44	Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 786-794.	0.7	16
45	Human-leukocyte antigen class II genes in early-onset obsessive-compulsive disorder. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 352-358.	2.6	16
46	Simultaneous genotyping of <i>CYP2C9</i> *2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 635-641.	1.9	15
47	ARVCF single marker and haplotypic association with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1064-1069.	4.8	15
48	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 32-42.	2.0	15
49	Effect of <i>CYP2D6</i> on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial. <i>Pharmacogenomics</i> , 2014, 15, 17-28.	1.3	14
50	Glutathione S-transferase (<i>GSTM1</i> and <i>GSTT1</i>)-dependent risk for colorectal cancer. <i>Anticancer Research</i> , 2002, 22, 3399-403.	1.1	14
51	Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2016, 16, 293-300.	2.0	13
52	Intuitive pharmacogenetic dosing of risperidone according to <i>CYP2D6</i> phenotype extrapolated from genotype in a cohort of first episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2017, 27, 647-656.	0.7	13
53	Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. <i>Pharmacogenomics</i> , 2010, 11, 1725-1731.	1.3	12
54	Searching for functional SNPs or rare variants in exonic regions of <i>DRD3</i> in risperidone-treated patients. <i>European Neuropsychopharmacology</i> , 2011, 21, 294-299.	0.7	12

#	ARTICLE	IF	CITATIONS
55	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2017, 95, 91-101.	3.1	12
56	Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. <i>Translational Psychiatry</i> , 2018, 8, 276.	4.8	12
57	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. <i>Journal of Psychopharmacology</i> , 2020, 34, 514-523.	4.0	12
58	Pi*S and Pi*Z alpha 1 antitrypsin polymorphism and the risk for asbestosis in occupational exposure to asbestos. <i>Toxicology Letters</i> , 2002, 136, 9-17.	0.8	11
59	Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 741-747.	1.9	11
60	Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example. <i>Pharmacogenomics</i> , 2015, 16, 1975-1988.	1.3	11
61	Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 711-718.	1.3	11
62	Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 487-496.	1.5	10
63	Association between genetic variants of serotonergic and glutamatergic pathways and the concentration of neurometabolites of the anterior cingulate cortex in paediatric patients with obsessive-compulsive disorder. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 394-404.	2.6	10
64	Decrease in specific micronutrient intake in colorectal cancer patients with tumors presenting Ki-ras mutation. <i>Anticancer Research</i> , 2004, 24, 2011-20.	1.1	10
65	Association of CACNA1C and SYNE1 in offspring of patients with psychiatric disorders. <i>Psychiatry Research</i> , 2016, 245, 427-435.	3.3	9
66	One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms. <i>Pharmacopsychiatry</i> , 2016, 49, 248-253.	3.3	9
67	Genetic variability in the serotonergic system and age of onset in anorexia nervosa and obsessive-compulsive disorder. <i>Psychiatry Research</i> , 2019, 271, 554-558.	3.3	9
68	The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. <i>Journal of Psychiatric Research</i> , 2020, 126, 8-18.	3.1	9
69	A functional variant provided further evidence for the association of <i>ARVCF</i> with schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1052-1059.	1.7	8
70	Impact of <i>NTRK2</i> , <i>DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. <i>Journal of Psychopharmacology</i> , 2018, 32, 702-710.	4.0	8
71	The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. <i>Psychopharmacology</i> , 2021, 238, 665-676.	3.1	8
72	Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort. <i>Schizophrenia Research</i> , 2022, 244, 101-110.	2.0	8

#	ARTICLE	IF	CITATIONS
73	Induction of NAD(P)H Quinone Oxidoreductase by Vegetables Widely Consumed in Catalonia, Spain. <i>Nutrition and Cancer</i> , 2005, 52, 49-58.	2.0	7
74	Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2009, 7, 59-69.	0.2	6
75	A common variant of the ABO gene protects against hypertension in a Spanish population. <i>Hypertension Research</i> , 2012, 35, 592-596.	2.7	6
76	Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 541-552.	4.5	6
77	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. <i>Schizophrenia Research</i> , 2020, 218, 292-294.	2.0	6
78	Concentration of hydroxyproline in blood: A biological marker in occupational exposure to asbestos and its relationship with Pi*Z and Pi*S polymorphism in the alpha-1 antitrypsin gene. <i>American Journal of Industrial Medicine</i> , 2004, 45, 186-193.	2.1	5
79	Genetic Associations of Serotonergic and GABAergic Genes in an Extended Collection of Early-Onset Obsessive-Compulsive Disorder Trios. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 152-157.	1.3	5
80	A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood. <i>Translational Psychiatry</i> , 2021, 11, 539.	4.8	5
81	Cancer, genes, and catechol estrogen metabolites. <i>International Journal of Clinical Oncology</i> , 2003, 8, 65-66.	2.2	4
82	Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. <i>Psychopharmacology</i> , 2020, 237, 2151-2159.	3.1	4
83	The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study. <i>European Neuropsychopharmacology</i> , 2022, 57, 105-117.	0.7	4
84	The effect of age on DNA concentration from whole saliva: Implications for the standard isolation method. <i>American Journal of Human Biology</i> , 2014, 26, 859-862.	1.6	3
85	DNA Methylation of Fluoxetine Response in Child and Adolescence: Preliminary Results. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 459-467.	0.7	3
86	Integrative DNA Methylation and Gene Expression Analysis of Cognitive Behavioral Therapy Response in Children and Adolescents with Obsessive-Compulsive Disorder; a Pilot Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 757-766.	0.7	3
87	Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data. <i>Frontiers in Pharmacology</i> , 2021, 12, 729474.	3.5	3
88	Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode. <i>Psychological Medicine</i> , 2023, 53, 4634-4647.	4.5	3
89	SiNoPsis: Single Nucleotide Polymorphisms selection and promoter profiling. <i>Bioinformatics</i> , 2018, 34, 303-305.	4.1	2
90	Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients. <i>NPJ Schizophrenia</i> , 2022, 8, .	3.6	2

#	ARTICLE	IF	CITATIONS
91	6.116 MONOCYTE ACTIVATION MARKERS IN OBSESSIVE-COMPULSIVE DISORDER. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S241.	0.5	1
92	Different Modulation of Rps6 Phosphorylation by Risperidone in Striatal Cells Sub Populations: Involvement of the mTOR Pathway in Antipsychotic-Induced Extrapyrimal Symptoms in Mice. Neuropsychiatry, 2018, 08, .	0.4	1
93	Gene expression study in monocytes: evidence of inflammatory dysregulation in early-onset obsessive-compulsive disorder. Translational Psychiatry, 2022, 12, 134.	4.8	1
94	Clinical improvement and plasma concentration of fluoxetine in major depression disorder, obsessive compulsory disorder and generalized anxiety disorder. Neuropsychiatrie De L'Enfance Et De L'Adolescence, 2012, 60, S185.	0.2	0
95	4.15 EPIGENETIC AND GENETIC VARIANTS IN THE HTR1B GENE AND CLINICAL IMPROVEMENT IN CHILDREN AND ADOLESCENTS TREATED WITH FLUOXETINE. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S167.	0.5	0
96	P.276 Altered frequency of T helper 17 cells and Treg cells in children and adolescents with obsessive-compulsive disorder. European Neuropsychopharmacology, 2019, 29, S205.	0.7	0
97	Response to fluoxetine in children and adolescents: a weighted gene co-expression network analysis of peripheral blood. American Journal of Translational Research (discontinued), 2020, 12, 2028-2040.	0.0	0
98	P.0606 Identification of key genes involved in antipsychotic-induced metabolic dysregulation based on integrative bioinformatics analysis of multi-tissue gene expression data. European Neuropsychopharmacology, 2021, 53, S445.	0.7	0